National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Dostarlimab (Jemperli®). HTA ID: 21045

Dostarlimab is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.

NCPE Assessment Process Complete
Rapid review commissioned 26/10/2021
Rapid review completed 30/11/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dostarlimab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 22/12/2021
Pre-submission consultation with Applicant Scheduled
Current Status Pre-submission consultation with Applicant scheduled